Transforming Myopia Treatment: Perry Sternberg Talks SYD-101

Click here to watch the video version of this podcast.

This week on The Rob & Jai Show, an edition of the OIS Podcast, Perry Sternberg, CEO of Sydnexis, discusses the company’s efforts to bring its innovative SYD-101 product to market, which aims to slow the progression of pediatric myopia.

🔹Challenges in Market Access: Sternberg emphasizes the challenges of market access and reimbursement, explaining that it’s not just about the product’s price but also the value proposition it offers.
🔹Launch Plans for 2026: The company is planning for a 2026 launch, following FDA approval, with a strong focus on ensuring a positive experience for both physicians and patients.
🔹Global Significance of SYD-101: He highlights the global significance of SYD-101, particularly in regions with high rates of myopia like Asia, where the need for effective solutions is critical.
🔹Personal Mission: Reflecting on his personal mission, Sternberg expresses his desire to make a meaningful impact on children’s vision and future health.

The hosts applaud his leadership and the potential of this product to make a lasting difference in the lives of patients affected by progressive myopia.

To learn more about SYD-101 and the exciting developments in pediatric myopia treatment, be sure to listen to the full podcast episode!

Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.

Resources:
Dr. Rob Rothman: https://ois.net/robert-rothman-md/
Dr. Jai Parekh: https://ois.net/jai-g-parekh-md-mba/
Perry Sternberg: https://ois.net/perry-sternberg/